• Publications
  • Influence
Multiple sclerosis--the plaque and its pathogenesis.
Substantial advances have elucidated some of the central mechanisms underlying the inflammation, demyelination, and neurodegeneration that occur in multiple sclerosis. Correspondingly, the clinicalExpand
  • 1,487
  • 89
  • PDF
Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis.
PURPOSE To examine the relation of visual function to retinal nerve fiber layer (RNFL) thickness as a structural biomarker for axonal loss in multiple sclerosis (MS), and to compare RNFL thicknessExpand
  • 571
  • 31
  • PDF
Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines
MS is a chronic recurrent inflammatory disorder of the CNS. The disease results in injury to the myelin sheaths, the oligodendrocytes, and, to a lesser extent, the axons and nerve cellsExpand
  • 671
  • 30
  • PDF
Immune surveillance in multiple sclerosis patients treated with natalizumab
Our objective was to test whether natalizumab, an antibody against very late activating antigen (VLA)‐4, interferes with central nervous system immune surveillance as assessed by leukocyte cellExpand
  • 392
  • 27
Quantitative sensory testing
Objective: This assessment evaluates the clinical utility, efficacy, and safety of quantitative sensory testing (QST). Methods: By searching MEDLINE, Current Contents, and their personal files, theExpand
  • 370
  • 22
Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies
Objective: To evaluate the retinal nerve fiber layer (RNFL) thickness and macular volume in neuromyelitis optica (NMO) spectrum patients using optical coherence tomography (OCT). Background: OCT canExpand
  • 228
  • 20
The Global Adherence Project (GAP): a multicenter observational study on adherence to disease‐modifying therapies in patients with relapsing‐remitting multiple sclerosis
Background:  Most disease‐modifying therapies (DMTs) for multiple sclerosis (MS) are self‐injectable medications that must be taken on an ongoing basis to reduce disease activity. Thus, adherence toExpand
  • 265
  • 17
  • PDF
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
BACKGROUND Treatment with natalizumab, a monoclonal antibody against the adhesion molecule very late activation antigen 4, an alpha4beta(1) integrin, was recently associated with the development ofExpand
  • 233
  • 14
  • PDF
Multiple sclerosis and the urologist.
PURPOSE We provide an updated reference detailing the neurological and urological state of the art approach to multiple sclerosis (MS) with special emphasis on the pathology and physiology, effectsExpand
  • 236
  • 14
Optical coherence tomography and disease subtype in multiple sclerosis
Objective: To examine retinal nerve fiber layer (RNFL) thickness, macular volumes (MV), and visual acuity in multiple sclerosis (MS) eyes, with and without history of acute optic neuritis (ON).Expand
  • 276
  • 13
  • PDF